Business Context and Reporting Period
This Form 8-K filing by Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reports a significant executive leadership change. The report date is March 11, 2025, with the event occurring on the same date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and related compensation agreements.
Material Changes
- Executive Appointment: Mr. Christopher Cooper was appointed as Interim Co-Chief Executive Officer (Interim Co-CEO) effective March 11, 2025.
- Leadership Structure: Dr. Anatoly Dritschilo, Chairman of the Board, will continue as Co-CEO, focusing on scientific and clinical trial activities, while Mr. Cooper will focus on capital markets and business capabilities.
- Compensation Agreement: The Company entered into a consulting agreement with Number 2 Capital Corp. (owned by Mr. Cooper). The agreement stipulates a compensation of $20,000 per month for a six-month term, requiring 40 hours of work per week.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or specific risk factors beyond the standard disclosure that the consulting agreement may be terminated by either party with 30 days' notice or immediately for cause. The appointment is intended to enhance the Company's capital markets and business capabilities.
Investor Verification Checklist
- Verify the full text of the Consulting Agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Confirm the press release details (Exhibit 99.1) for any further public commentary on the strategic rationale.
- Review Mr. Cooper's background regarding his current role at First Towers & Fiber Corp. and past experience at Aroway Energy to assess potential conflicts of interest or time allocation.
- Monitor future filings for the impact of this leadership change on the company's capital raising efforts and operational strategy.